Future of the pharmacogenomics of calcineurin inhibitors in renal transplant patients

被引：6
|
作者：
Zhu, Huaijun [1 ]
Ge, Weihong [1 ]
机构：
[1] Nanjing Univ, Affiliated Nanjing Drum Tower Hosp, Sch Med, Dept Pharm, Nanjing 210008, Jiangsu, Peoples R China
来源：
PHARMACOGENOMICS | 2011年 / 12卷 / 11期
关键词：
calcineurin inhibitor; epigenetics; orphan nuclear receptor; pharmacogenomics; renal transplantation; REGULATED GENE-EXPRESSION; RECIPIENTS; THERAPY; PHARMACOKINETICS; PHARMACODYNAMICS; PERSPECTIVES; CELLS; CYP3A;
D O I：
10.2217/PGS.11.129
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1505 / 1508
页数：4
相关论文
共 50 条
  • [41] Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients
    Quteineh, Lina
    Verstuyft, Celine
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2010, 15 (05) : 601 - 607
  • [42] Calcineurin inhibitors and male fertility after renal transplantation - a review
    Georgiou, G. K.
    Dounousi, E.
    Harissis, H. V.
    ANDROLOGIA, 2016, 48 (05) : 483 - 490
  • [43] Calcineurin inhibitor toxicity in a renal transplant recipient
    Charney, Douglas A.
    Bhaskaran, Madhu
    Molmenti, Ernesto
    CLINICAL KIDNEY JOURNAL, 2009, 2 (02): : 175 - 176
  • [44] Long-term Results of Conversion From Calcineurin Inhibitors to Sirolimus in 150 Maintenance Kidney Transplant Patients
    Garrouste, Cyril
    Kamar, Nassim
    Guilbeau-Frugier, Celine
    Guitard, Joelle
    Esposito, Laure
    Lavayssiere, Laurence
    Nogier, Marie-Beatrice
    Cointault, Olivier
    Ribes, David
    Rostaing, Lionel
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2012, 10 (02) : 110 - 118
  • [45] Calcineurin Inhibitors in Renal TransplantationWhat is the Best Option?
    Kazunari Tanabe
    Drugs, 2003, 63 : 1535 - 1548
  • [46] Calcineurin inhibitors alter the osmotic properties of erythrocytes in patients after renal transplantation
    Wrobel, Anna
    Kaminska, Dorota
    Sieranska, Marta
    Dryjanska, Agata
    Kedzierska, Jadwiga
    Klinger, Marian
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2008, 17 (02): : 213 - 216
  • [47] A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients
    Zheng, Xiang
    Zhang, Weijie
    Zhou, Hua
    Cao, Ronghua
    Shou, Zhangfei
    Zhang, Shuwei
    Cheng, Ying
    Chen, Xuchun
    Ding, Chenguang
    Tang, Zuofu
    Li, Ning
    Shi, Shaohua
    Zhou, Qiang
    Chen, Qiuyuan
    Chen, Gang
    Chen, Zheng
    Zhou, Peijun
    Hu, Xiaopeng
    Zhang, Xiaodong
    Na, Ning
    Wang, Wei
    CHINESE MEDICAL JOURNAL, 2022, 135 (13) : 1597 - 1603
  • [48] Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients
    Felipe, Claudia
    Ferreira, Alexandra
    Bessa, Adrieli
    Abait, Tamiris
    Perez, Juliana D.
    Casarini, Dulce Elena
    Medina-Pestana, Jose
    Tedesco, Helio
    THERAPEUTIC DRUG MONITORING, 2018, 40 (01) : 52 - 58
  • [49] The future of thiopurine pharmacogenomics
    Duley, John A.
    Somogyi, Andrew A.
    Martin, Jennifer H.
    PHARMACOGENOMICS, 2012, 13 (14) : 1549 - 1552
  • [50] CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study
    Gervasini, Guillermo
    Garcia-Pino, Guadalupe
    Vergara, Esther
    Mota-Zamorano, Sonia
    Garcia-Cerrada, Montserrat
    Luna, Enrique
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (01) : 53 - 60
12345